Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the addition of intranasal oxytocin to the treatment of Major Depression using interpersonal psychotherapy. Half of the participants will receive a placebo adjunct to interpersonal psychotherapy, and the other half will receive oxytocin.
Depression is a debilitating mental health condition that carries great consequences for both the individual and society. Crucially, at least one third of depressed patients do not respond to existing interventions and relapse rates are high, alerting scientists to the need to explore possible adjunctive treatments and novel therapeutic targets. In this regard, research on the use of oxytocin in the treatment of depression is promising.
It is well documented that interpersonal stress predicts the onset of depression, and that social isolation is a symptom of psychological distress that can leave patients with a poor prognosis for recovery. Therapeutic interventions focused on the alleviation of social conflict and strengthening of social bonds (i.e. Interpersonal Psychotherapy; IPT) show greater efficacy for the treatment of depression than other psychological interventions (NIMH Treatment of Depression Collaborative Research Program; Elkin et al. 1984). It has been posited that oxytocin, a naturally produced hormone that is involved in social-support seeking and stress-regulation, could represent a biological link between social stress and depression in adulthood. The salubrious effect of exogenous oxytocin on human social behavior is well documented: Oxytocin has been shown to make individuals feel more securely attached in their social relationships, increase their trust in others and openness to new ideas, improve their recall of specific and positive social autobiographical memories, and improve social learning. Importantly, these factors have been shown to improve the efficacy of Interpersonal Psychotherapy. Thus, It stands to reason that the use of oxytocin as an adjunct to IPT could improve its efficacy for the treatment of depression, which is an important prospect when considering that a third of patients do not respond to existing therapies.
In the proposed research project, we will conduct a Randomized Controlled Trial for the treatment of Major Depression with IPT and adjunctive oxytocin. Patients will be screened for eligibility, undergo structured psychotherapy for twelve weeks, and will be followed longitudinally for changes in quality of social functioning, interpersonal stress, psychiatric symptoms and depressive relapse. Establishing novel interventions for depression could position healthcare providers to better alleviate the burden and personal suffering caused by this disorder.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Spray And Interpersonal Psychotherapy | Placebo Comparator | Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). |
|
| Oxytocin Spray And Interpersonal Psychotherapy | Experimental | Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxytocin nasal spray or placebo | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score] | Diagnosis of Major Depressive Episode Will Be Diagnosed Using The SCID-IV | Baseline, 4 months later (following therapy) |
| Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D)[Change Score] | Hamilton Rating Scale for Depression (HRS-D) | Baseline, 4 months later (following therapy) |
| Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score] | Inventory for Depressive Symptomology (IDS-C) | Baseline, 4 months later (following therapy) |
| Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score] | Global Axis of Functioning using the SCID-IV (GAF) | Baseline, 4 months later (following therapy) |
| Patient dropout rate [Number of sessions missed] | patient dropout rate | includes baseline up to 4 months following baseline assessment (until the end of therapy) |
| Depressive Symptoms (patient-rated) (Beck Depression Inventory-II (BDI-II) [Change Score] | Baseline up to 10 months later (slope of change over time) | |
| Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score] | Diagnosis of Major Depressive Episode Will Be Diagnosed Using The SCID-IV |
| Measure | Description | Time Frame |
|---|---|---|
| Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score] | UCLA Life Stress Interview - Chronic Stress Module (UCLA) | Baseline, 4 months later (following therapy) |
| Biological stress reactivity (Daily Diurnal Cortisol) [Change Score] |
| Measure | Description | Time Frame |
|---|---|---|
| Moderation by personality (NEO-PI-R) | NEO-PI-R; Moderation by extraversion | Baseline |
| Mediation by personality (NEO-PI-R) [Change Score] | NEO-PI-R; Mediation by extraversion |
Inclusion Criteria
• Current Major Depressive Episode
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Concordia University | Montreal | Quebec | H4B 1R6 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38445382 | Derived | Ellenbogen MA, Cardoso C, Serravalle L, Vadaga K, Joober R. The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial. Psychol Med. 2024 Jul;54(9):2122-2132. doi: 10.1017/S0033291724000217. Epub 2024 Mar 6. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D010121 | Oxytocin |
| ID | Term |
|---|---|
| D010909 | Pituitary Hormones, Posterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 4 months later (following therapy) and 10 months later (6 months following therapy) |
| Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D) [Change Score] | Hamilton Rating Scale for Depression (HRS-D) | 4 months later (following therapy) and 10 months later (6 months following therapy) |
| Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score] | Inventory for Depressive Symptomology (IDS-C) | 4 months later (following therapy) and 10 months later (6 months following therapy) |
| Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score] | Global Axis of Functioning using the SCID-IV (GAF) | 4 months later (following therapy) and 10 months later (6 months following therapy) |
Daily Diurnal Cortisol (2 days) |
| Baseline, 4 months later (following therapy) |
| Working alliance (clinician-rated) (Working Alliance Inventory (WAI) [Change Score] | Working Alliance Inventory (WAI) | Baseline up to 4 months later (slope of change over time) |
| Social functioning (patient-rated) (Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS) COMPOSITE SCORE [Change Score] | Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS | Baseline up to 10 months later (slope of change over time) |
| Stress (patient-rated) (Perceived Stress Scale (PSS) [Change Score] | Perceived Stress Scale (PSS) | Baseline up to 10 months later (slope of change over time) |
| Anxiety (patient-rated) (Beck Anxiety Inventory (BAI) [Change Score] | Beck Anxiety Inventory (BAI) | Baseline up to 10 months later (slope of change over time) |
| Therapeutic Alliance (patient-rated) (Working Alliance Inventory (WAI) | Working Alliance Inventory (WAI) | Baseline up to 4 months later (slope of change over time) |
| Usefulness of Therapy (patient-rated); COMPOSITE SCORE | Measure by score on Helpful Aspects of Therapy (HAT) | Baseline up to 4 months later (slope of change over time) |
| Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score] | UCLA Life Stress Interview - Chronic Stress Module (UCLA) | 4 months later (following therapy) and 10 months later (6 months following therapy) |
| Biological stress reactivity (Daily Diurnal Cortisol) [Change Score] | Daily Diurnal Cortisol (2 days) | 4 months later (following therapy) and 10 months later (6 months following therapy) |
| Baseline up to 10 months later [Slope of Change] |
| Moderation by attachment (ECR, AAI) [COMPOSITE SCORE] | ECR, AAI: Moderation by attachment style | Baseline |
| Moderation by attachment (ECR, AAI) [COMPOSITE SCORE] | ECR, AAI: Mediation by attachment style | Baseline up to 10 months later [Slope of Change] |
| Adverse Events [Average Score] COMPOSITE | In-house measure of adverse events weekly | baseline up to 4 months |
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |